Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2013008313
pages 25-32

Current Molecular Targets for Urological Cancer

Yutaka Horiguchi
Department of Urology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023 Tokyo, Japan

RÉSUMÉ

Clinically advanced stages of urological cancers are currently treated with conventional surgery, radiation, and chemotherapy. As for molecular targets, multiple kinase inhibitors (MKIs) and mammalian target of rapamycin (mTOR) inhibitors have already been introduced to treat advanced metastatic renal cell carcinoma, which is refractory to cytokine therapies such as interferon-α and interleukin-2. In recent trends in cancer research, the translation of basic science into clinical application has been accelerated. In this review, new molecular targets, such as MKIs, mTOR inhibitors, along with the phosphatidylinositol 3-kinase (PI3K)/ Akt signaling pathway, vascular endothelial growth factor (VEGF), and NF-κB, as well as conventional COX inhibitors, are overviewed. As the putative source of cancer oncogenesis, cancer stem cells (CSCs) have been highlighted in recent research. Current understandings of CSCs in urologic oncology are also discussed.


Articles with similar content:

Cellular Iron Metabolism in Prognosis and Therapy of Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 5
Frank M. Torti, Suzy V. Torti
Resistance to Cell Death and Its Modulation in Cancer Stem Cells
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Ahmad R. Safa
IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Ali Bettaieb, Stéphanie Plenchette, Laurence Dubrez, Sarra Bouaouiche
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida
Role of NF-κB in Tumorigenesis
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 2
Gautam Sethi, Muthu K. Shanmugam, Alan P. Kumar, Benny K. H. Tan